RNAC Stock Overview
A clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cartesian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.44 |
| 52 Week High | US$41.87 |
| 52 Week Low | US$8.85 |
| Beta | 0 |
| 1 Month Change | -2.16% |
| 3 Month Change | -43.63% |
| 1 Year Change | -51.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.48% |
Recent News & Updates
Subdued Growth No Barrier To Cartesian Therapeutics, Inc. (NASDAQ:RNAC) With Shares Advancing 27%
May 04
Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 18Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies
Jan 17Recent updates
Subdued Growth No Barrier To Cartesian Therapeutics, Inc. (NASDAQ:RNAC) With Shares Advancing 27%
May 04Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 18Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies
Jan 17Risks Still Elevated At These Prices As Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Dive 33%
Jan 05Cartesian Therapeutics: Uncertainty Remains
Nov 10Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Sep 17Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data
Jul 02Shareholder Returns
| RNAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.1% | -8.7% | 0.3% |
| 1Y | -51.3% | -15.3% | 8.0% |
Return vs Industry: RNAC underperformed the US Biotechs industry which returned -15.3% over the past year.
Return vs Market: RNAC underperformed the US Market which returned 8% over the past year.
Price Volatility
| RNAC volatility | |
|---|---|
| RNAC Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: RNAC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RNAC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 66 | Carsten Brunn | www.cartesiantherapeutics.com |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma.
Cartesian Therapeutics, Inc. Fundamentals Summary
| RNAC fundamental statistics | |
|---|---|
| Market cap | US$256.95m |
| Earnings (TTM) | -US$38.31m |
| Revenue (TTM) | US$34.17m |
7.9x
P/S Ratio-7.1x
P/E RatioIs RNAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNAC income statement (TTM) | |
|---|---|
| Revenue | US$34.17m |
| Cost of Revenue | US$50.04m |
| Gross Profit | -US$15.87m |
| Other Expenses | US$22.44m |
| Earnings | -US$38.31m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.48 |
| Gross Margin | -46.43% |
| Net Profit Margin | -112.11% |
| Debt/Equity Ratio | 0% |
How did RNAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 02:01 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cartesian Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| John Newman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |